Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$223.35 USD
-7.89 (-3.41%)
Updated May 24, 2022 04:00 PM ET
3-Hold of 5 3
B Value A Growth D Momentum B VGM
- YR Estimate
- 12/31/2021
- 12/31/2020
- 12/31/2019
- 12/31/2018
- 12/31/2017
- Revenue - Line of Business (LOBR)
- Net sales related to products
- 784.58
- 627.78
- 591.86
- 578.16
- 559.30
- Revenue - Line of Business (LOBR)
- Net sales-Research Models and Services
- 690.44
- 571.15
- 537.09
- 519.68
- 493.62
- Revenue - Line of Business (LOBR)
- Net sales related to services
- 2,755.58
- 2,296.16
- 2,029.37
- 1,687.94
- 1,298.30
- Revenue - Line of Business (LOBR)
- Net sales- Discovery and safety assessment
- 2,107.23
- 1,837.43
- 1,619.00
- 1,316.85
- 980.02
- Revenue - Line of Business (LOBR)
- Net sales- Manufacturing support
- 742.49
- 515.35
- 465.14
- 429.56
- 383.96
- Income - Line of Business (LOBI)
- Operating income - Research Models and Services
- 188.50
- 102.71
- 133.91
- 136.47
- 114.71
- Income - Line of Business (LOBI)
- Operating income - Discovery and safety assessment
- 499.21
- 325.96
- 258.90
- 227.58
- 184.06
- Income - Line of Business (LOBI)
- Operating income - Manufacturing support
- 254.21
- 181.49
- 145.42
- 136.21
- 123.90
- Income - Line of Business (LOBI)
- Operating income - Unallocated Corporate Overhead
- -230.32
- -177.40
- -187.08
- -168.87
- -133.00